The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
The public health summit in Addis Ababa will bring together policymakers, scientists, healthcare leaders, and global partners
The clinical study in France evaluated the safety and feasibility of Robocath’s robotic-assisted coronary intervention platform across complex cardiac cases.
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
NEJM study shows strong protection across strains
The leading cancer hospital urges carrier screening to prevent thalassemia burden
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
Subscribe To Our Newsletter & Stay Updated
